Table 1

 Neonatal simulations of HFA-BDP and CFC-BDP delivery through an endotracheal tube using the Neonatal Chamber-Ventilator System or the Neonatal Chamber (simulations 1–3) and using the Neonatal Chamber and face mask without and with manual ventilation assistance (simulations 4 and 5)

FormulationSimulation 1Simulation 2Simulation 3Simulation 4Simulation 5
Dose delivered is expressed as mean (SD) total emitted dose (TED) (μg) and efficiency (TED/label claim dose) (%). Three actuations/measurement; 5 measurements per holding chamber × 3 holding chambers per simulation  =  15 samples per simulation. Simulation 1, Mechanical ventilation, 40% relative humidity (NCVS/ET); simulation 2, mechanical ventilation, 100% relative humidity (NCVS/ET); simulation 3, manual ventilation (NC/ET); simulation 4, no manual ventilation assistance (NC/face mask); simulation 5, manual ventilation assistance (NC/face mask).
*Simulation 1 and 2 v 3, p<0.001; 4 v 5, p<0.001.
**Simulation 1 v 3, p  =  0.003; 2 v 3, p<0.001; 4 v 5, p<0.001.
HFA-BDP, Hydrofluoroalkane-beclomethasone; CFC-BDP, chlorofluorocarbon-beclomethasone; ET, endotracheal tube; NCVS, Neonatal Chamber-Ventilator System; NC, Neonatal Chamber.
HFA-BDP*4.4 (0.7) (8.8%)1.5 (0.2) (3.0%)6.5 (0.6) (13.0%)4.1 (1.6) (8.2%)26.6 (3.1) (53.2%)
CFC-BDP**0.4 (0.3) (0.8%)0.02 (0.08) (0.04%)1.3 (0.5) (2.6%)2.3 (0.7) (4.6%)21.6 (4.3) (43.2%)
p Value<0.0001<0.0001<0.00010.00070.0011